Limits...
Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis.

Li J, Ju Y - Iran J Med Sci (2015)

Bottom Line: However, the published studies have produced contentious and controversial results.TT=1.01, 95% CI=0.93-1.09, Ph=1.00).Larger well-designed studies with gene-to-gene and gene-to-environment interactions are clearly required to validate the results further.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiotherapy, The Second Affiliated Hospital of Nantong University, Nantong University, Nantong 226001, Jiangsu Province, China.

ABSTRACT
The vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphism involved in the regulation of the protein levels has been implicated in breast cancer. However, the published studies have produced contentious and controversial results. Herein, we performed a meta-analysis (from January to October 2013); to further evaluate the association between +936 C/T polymorphism and the risk of breast cancer. By searching the EMBASE, PubMed, and Web of Science databases, we identified a total of 12 case-control studies with 8,979 cancer patients and 9,180 healthy controls. The strength of the association was assessed using Odds Ratios (ORs) with 95% Confidence Intervals (CI). We found no evidence indicating that the allelic model or the genotype models of +936 C/T polymorphism were associated with the risk of breast cancer in total population (ORCC vs. TT=1.01, 95% CI=0.96-1.06, Ph=1.00; ORCC+CT vs. TT=1.00, 95% CI=0.96-1.05, Ph=1.00; ORCC vs. CT+TT=1.02, 95% CI=0.98-1.07, Ph=0.94; OR allele C vs. allele T=1.01, 95% CI=0.98-1.04, Ph=0.99; ORCT vs. TT=1.01, 95% CI=0.93-1.09, Ph=1.00). Such lack of association with breast cancer was also observed in subgroup analyses according to ethnicity as well as in the analysis by source of controls. In conclusion, this meta-analysis suggests that the functionally important +936 C/T polymorphism may not be associated with breast cancer risk. Larger well-designed studies with gene-to-gene and gene-to-environment interactions are clearly required to validate the results further.

No MeSH data available.


Related in: MedlinePlus

ORs of overall breast cancer risks associated with +936 C/T polymorphism under CC vs. TT model by fixed effects for each of the 12 included studies. For each study, the estimates of OR and its 95% CI were plotted with a box and a horizontal line. ♦: Pooled OR and its 95% CI
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4300476&req=5

Figure 2: ORs of overall breast cancer risks associated with +936 C/T polymorphism under CC vs. TT model by fixed effects for each of the 12 included studies. For each study, the estimates of OR and its 95% CI were plotted with a box and a horizontal line. ♦: Pooled OR and its 95% CI

Mentions: The main outcomes of this meta-analysis for +936 C/T polymorphism are listed in table 2. We found no evidence indicating that +936 C/T polymorphism were significantly associated with the risk of breast cancer in total population when using CC vs. TT (OR=1.01, 95% CI=0.96-1.06, Ph=1.00). To test whether there is a positive association in another contrast models we subsequently assumed the CC+CT vs. TT model, failing to find any significant association (OR=1.00, 95% CI=0.96-1.05, Ph=1.00). In terms of the remaining models tested, the statistical data showed no clear associations with the genetic risk of breast cancer (ORCC vs. CT+TT=1.02, 95% CI=0.98-1.07, Ph=0.94; OR allele C vs. allele T=1.01, 95% CI=0.98-1.04, Ph=0.99; ORCT vs. TT=1.01, 95% CI=0.93-1.09, Ph=1.00) (see figure 2 and figure 3).


Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis.

Li J, Ju Y - Iran J Med Sci (2015)

ORs of overall breast cancer risks associated with +936 C/T polymorphism under CC vs. TT model by fixed effects for each of the 12 included studies. For each study, the estimates of OR and its 95% CI were plotted with a box and a horizontal line. ♦: Pooled OR and its 95% CI
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4300476&req=5

Figure 2: ORs of overall breast cancer risks associated with +936 C/T polymorphism under CC vs. TT model by fixed effects for each of the 12 included studies. For each study, the estimates of OR and its 95% CI were plotted with a box and a horizontal line. ♦: Pooled OR and its 95% CI
Mentions: The main outcomes of this meta-analysis for +936 C/T polymorphism are listed in table 2. We found no evidence indicating that +936 C/T polymorphism were significantly associated with the risk of breast cancer in total population when using CC vs. TT (OR=1.01, 95% CI=0.96-1.06, Ph=1.00). To test whether there is a positive association in another contrast models we subsequently assumed the CC+CT vs. TT model, failing to find any significant association (OR=1.00, 95% CI=0.96-1.05, Ph=1.00). In terms of the remaining models tested, the statistical data showed no clear associations with the genetic risk of breast cancer (ORCC vs. CT+TT=1.02, 95% CI=0.98-1.07, Ph=0.94; OR allele C vs. allele T=1.01, 95% CI=0.98-1.04, Ph=0.99; ORCT vs. TT=1.01, 95% CI=0.93-1.09, Ph=1.00) (see figure 2 and figure 3).

Bottom Line: However, the published studies have produced contentious and controversial results.TT=1.01, 95% CI=0.93-1.09, Ph=1.00).Larger well-designed studies with gene-to-gene and gene-to-environment interactions are clearly required to validate the results further.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiotherapy, The Second Affiliated Hospital of Nantong University, Nantong University, Nantong 226001, Jiangsu Province, China.

ABSTRACT
The vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphism involved in the regulation of the protein levels has been implicated in breast cancer. However, the published studies have produced contentious and controversial results. Herein, we performed a meta-analysis (from January to October 2013); to further evaluate the association between +936 C/T polymorphism and the risk of breast cancer. By searching the EMBASE, PubMed, and Web of Science databases, we identified a total of 12 case-control studies with 8,979 cancer patients and 9,180 healthy controls. The strength of the association was assessed using Odds Ratios (ORs) with 95% Confidence Intervals (CI). We found no evidence indicating that the allelic model or the genotype models of +936 C/T polymorphism were associated with the risk of breast cancer in total population (ORCC vs. TT=1.01, 95% CI=0.96-1.06, Ph=1.00; ORCC+CT vs. TT=1.00, 95% CI=0.96-1.05, Ph=1.00; ORCC vs. CT+TT=1.02, 95% CI=0.98-1.07, Ph=0.94; OR allele C vs. allele T=1.01, 95% CI=0.98-1.04, Ph=0.99; ORCT vs. TT=1.01, 95% CI=0.93-1.09, Ph=1.00). Such lack of association with breast cancer was also observed in subgroup analyses according to ethnicity as well as in the analysis by source of controls. In conclusion, this meta-analysis suggests that the functionally important +936 C/T polymorphism may not be associated with breast cancer risk. Larger well-designed studies with gene-to-gene and gene-to-environment interactions are clearly required to validate the results further.

No MeSH data available.


Related in: MedlinePlus